Infections in patients with rheumatoid arthritis treated with biologic agents. - Wikidata - wikimedia - TriplyDB

Infections in patients with rheumatoid arthritis treated with biologic agents.

Infections in patients with rheumatoid arthritis treated with biologic agents.

http://www.wikidata.org/entity/Q44952372

about

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis New insights into the impact of neuro-inflammation in rheumatoid arthritis What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Biologics registers in RA: methodological aspects, current role and future applications.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Ten years with biologics: to whom do data on effectiveness and safety apply?Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Initiation of rheumatoid arthritis treatments and the risk of serious infections.Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review.Abatacept treatment for rheumatoid arthritis Update on the treatment of ankylosing spondylitis.Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis Interactions between the immune and nervous systems in pain.Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia Infliximab: 12 years of experience The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.

P2860

Q26774173-0A4D7724-97AE-4A33-AFA4-F19087E66796 Q27023946-0ED235DA-C8BF-42D9-AAE5-65DABF09016F Q28074148-32DBE0F1-8140-4FE8-ACBC-8BC9E2DA2A0C Q28751012-99B8B96A-8A8C-4179-BB88-23B6739FE81C Q30009390-09C03D84-1AE4-4BCE-84D9-9A135FBDC94D Q30234303-9A239E60-F25D-48B3-96BF-8E59C023361E Q30240183-EA0B3997-EDE9-4530-AB45-2597B45E07D2 Q30680371-57EE5BF0-D8D9-4FEC-B297-3CD4A0992A85 Q30717002-F81E9291-A228-47EE-ABF2-3F72B20CB85E Q30990764-29DDF367-F91D-405D-99F9-E98C6EB0B187 Q31107094-45F8380A-823A-480C-BB86-CC6E521C0CD7 Q31122982-1238D6D8-B8F3-4E9F-9524-4F684C3FEF3A Q31123685-52BF221A-F2C0-4FC6-92AF-93514C13EB46 Q31151183-4438D05C-50D8-46BD-BBD3-BE173B482DA6 Q33315300-EF15374C-4020-49EA-8DED-B72A55941295 Q33529391-792E16D7-CCE4-4105-9860-E7BF33A27A07 Q33573112-E816EB42-8957-4420-890A-8F41437899E6 Q33749195-3E9110F7-69A6-4975-86BA-A2878009D295 Q33778719-4EB3278D-90BE-4602-BC16-D78FBD7042B7 Q33819684-41DBB575-D0F8-4854-8127-B7712F36E5D8 Q33923452-1FA68ADF-C097-45E3-8A42-86E5682C3680 Q34019267-ECF23528-E264-48F1-A582-04CC08DE930F Q34065002-ACB2C150-0E35-4BFB-95B1-81CB34014968 Q34216770-6BB3A6F2-EA74-4BA1-AFCC-8AFF7ABCF147 Q34413239-14077B28-AE95-4FC8-817A-E969C20D8350 Q34504816-9711360F-DE8A-44FD-AC4A-F722658A77E5 Q34588972-7A4A482F-0313-4EDD-9F51-9873CC7B4031 Q34592673-674CA51E-1EE5-483D-863B-F8C472D13FEF Q34641300-9CC8D498-8563-4E1D-8F28-71C23A50EA6A Q34643625-B1FAB633-54D0-4FF7-B983-D0A3D31B753B Q34792330-7B621AFE-1DEB-4281-9061-73062249918B Q34799654-FAD68E56-6AE2-48A4-97E8-649A4DE8C758 Q34818636-B3D6E51F-DD67-49A7-BC10-FCDC6B31D017 Q34897423-AEAB60E4-FA8F-4B30-8C72-7611848E5202 Q34984568-3A246B6F-83E2-4960-B8C7-D2F43278E89A Q35018415-64AA0245-E6EC-4E2F-AA10-FE2848225B52 Q35070446-C5250BE3-4AEF-44A2-9375-D807B4257A73 Q35082559-E2F28958-32D0-4484-A4EE-770782BF4433 Q35103988-6B31A4F2-D736-44B9-9359-FD4A0A5803F4 Q35152199-2744A06A-AFB1-46E5-BAD1-4EF556D7C4E4

P2860

Infections in patients with rheumatoid arthritis treated with biologic agents.

http://www.wikidata.org/entity/Q44952372

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Infections in patients with rheumatoid arthritis treated with biologic agents.

@en

Infections in patients with rheumatoid arthritis treated with biologic agents.

@nl

type

label

Infections in patients with rheumatoid arthritis treated with biologic agents.

@en

Infections in patients with rheumatoid arthritis treated with biologic agents.

@nl

prefLabel

Infections in patients with rheumatoid arthritis treated with biologic agents.

@en

Infections in patients with rheumatoid arthritis treated with biologic agents.

@nl

P1433

Q44952372-A95079E0-2B4D-4A60-894B-6BAC5E976BCB

P1476

Q44952372-83D0916D-B67C-474E-A8AE-6A7A30091D5C

P2093

Q44952372-3459028A-E881-4FFB-8E1B-F90A9928B158

Q44952372-4118394D-50E8-4427-A456-0C08462524C5

Q44952372-7E1274EE-9DD2-4EA6-94F2-36B88B2FE051

Q44952372-95E9B480-C29F-4E21-A0C1-4A9D7D53182A

Q44952372-9C5BA6B8-068C-4BCB-A0A5-FFB0D0EF91DC

Q44952372-B2CF3422-44A1-4995-A540-B498E3D6F691

Q44952372-B513F474-B2CC-4759-B3E2-81C4DF20540B

Q44952372-C295AB15-4CEC-4134-BCB0-1EB101B2245A

Q44952372-E3CC98A9-7529-4ABC-B9C7-67BCAFA068EC

Q44952372-E730265D-3E0A-4757-8166-356D52D59866

P304

Q44952372-33ABF0FA-2DD0-46CE-8D12-86B9B561D032

P31

Q44952372-FEFBE019-C957-4C69-A55A-76BE49EC8847

P356

Q44952372-B7A82659-BA74-4905-84E2-609BAAF64516

P433

Q44952372-4917556E-1E58-4733-B640-82E41B2B7A79

P478

Q44952372-2849E9F5-3611-4389-A1B4-09213A7C8D86

P577

Q44952372-E5DF9663-9CB8-4E71-84F5-3E18D3F2FEE2

P5875

Q44952372-AC561066-A2F2-496B-9AE5-3790D0DA4699

P698

Q44952372-BC256A9E-7760-42A9-9FE9-3AFE6C6721BF

P921

Q44952372-A9CEDD18-1D2B-4FD4-9EFE-62084F7546B0

P356

P1433

Arthritis & Rheumatology

P1476

Infections in patients with rheumatoid arthritis treated with biologic agents.

@en

P2093

Angela Zink

http://www.w3.org/2001/XMLSchema#string

Anja Strangfeld

http://www.w3.org/2001/XMLSchema#string

Christian Antoni

http://www.w3.org/2001/XMLSchema#string

Erika Gromnica-Ihle

http://www.w3.org/2001/XMLSchema#string

Joachim Listing

http://www.w3.org/2001/XMLSchema#string

Jörn Kekow

http://www.w3.org/2001/XMLSchema#string

Maria Stoyanova-Scholz

http://www.w3.org/2001/XMLSchema#string

Matthias Schneider

http://www.w3.org/2001/XMLSchema#string

Peter Herzer

http://www.w3.org/2001/XMLSchema#string

Rolf Rau

http://www.w3.org/2001/XMLSchema#string

P304

3403-3412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.21386

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7511921

http://www.w3.org/2001/XMLSchema#string

P698

16255017

http://www.w3.org/2001/XMLSchema#string

P921